{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:13:01Z","timestamp":1791097981853,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtct.2022.04.009","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T12:04:14Z","timestamp":1649851454000},"page":"374.e1-374.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-1413","authenticated-orcid":false,"given":"Evgeny","family":"Klyuchnikov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Badbaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwan","family":"Massoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Fritzsche-Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wolschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.04.009_bib0001","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/bloodadvances.2020001904","article-title":"Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation","volume":"4","author":"Grimm","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.04.009_bib0002","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bbmt.2014.04.003","article-title":"Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time","volume":"20","author":"Tang","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0004","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.exphem.2010.08.006","article-title":"Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia","volume":"38","author":"Wiedemann","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0005","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bmt.1704444","article-title":"Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective","volume":"33","author":"Bader","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0006","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.leu.2403719","article-title":"Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation","volume":"19","author":"Zeiser","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","article-title":"Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia","volume":"39","author":"Huisman","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0008","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0009","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.20693","article-title":"Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y chromosome-specific sequences","volume":"81","author":"Koldehoff","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/bmt.2014.254","article-title":"Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict posttransplant relapse in acute leukemia","volume":"50","author":"Jacque","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0011","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.bbmt.2017.05.031","article-title":"Clinical utility of quantitative PCR for chimerism and engraftment monitoring after allogeneic stem cell transplantation for hematologic malignancies","volume":"23","author":"Ahci","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.bmt.1704715","article-title":"How and when should we monitor chimerism after allogeneic stem cell transplantation?","volume":"35","author":"Bader","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0013","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.leu.2403622","article-title":"Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion\/deletion polymorphisms","volume":"19","author":"Jim\u00e9nez-Velasco","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0014","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.leu.2402017","article-title":"Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation","volume":"15","author":"Lion","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.leu.2402343","article-title":"Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation","volume":"16","author":"Schaap","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0016","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3109\/10428194.2013.789508","article-title":"Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (complete chimerism versus low level mixed chimerism) in acute leukemia","volume":"54","author":"Rossi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.04.009_bib0017","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.leu.2402550","article-title":"Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation","volume":"16","author":"P\u00e9rez-Sim\u00f3n","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0018","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjh.14008","article-title":"Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?","volume":"173","author":"Pichler","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0019","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/sj.leu.2403507","article-title":"Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis","volume":"18","author":"Scheffold","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0020","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","article-title":"Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation","volume":"94","author":"Bornh\u00e4user","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.04.009_bib0021","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s41375-019-0624-4","article-title":"Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation","volume":"34","author":"Bouvier","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0022","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0023","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0024","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ejh.13557","article-title":"Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML","volume":"106","author":"Klyuchnikov","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0026","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.04.009_bib0027","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bbmt.2012.01.012","article-title":"Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism","volume":"18","author":"Kwon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0028","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/leu.2010.283","article-title":"Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning","volume":"25","author":"Lange","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.009_bib0029","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.009_bib0030","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0031","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.009_bib0032","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/blood.V99.12.4618","article-title":"Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction","volume":"99","author":"Alizadeh","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.009_bib0033","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1089\/152581601750289028","article-title":"Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation","volume":"10","author":"Fehse","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.jtct.2022.04.009_bib0034","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.exphem.2008.09.014","article-title":"Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation","volume":"37","author":"Bacher","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0035","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","article-title":"Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation","volume":"55","author":"Othus","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0036","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/08880018.2020.1717697","article-title":"Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?","volume":"37","author":"Cousin","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0037","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/10428194.2020.1827249","article-title":"Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?","volume":"62","author":"Mountjoy","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.04.009_bib0038","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.10971","article-title":"Predictive factors and impact of full donor T-cell chimerism after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"92","author":"Mohty","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.04.009_bib0039","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.leukres.2013.01.010","article-title":"Post-transplant T cell chimerism predicts graft-versus-host disease but not disease relapse in patients undergoing an alemtuzumab-based reduced-intensity conditioned allogeneic transplant","volume":"37","author":"Nikolousis","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2022.04.009_bib0040","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/bmt.2013.2","article-title":"CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT","volume":"48","author":"Rosenow","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0041","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0042","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0043","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.009_bib0044","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.009_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ejh.12336","article-title":"Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation","volume":"93","author":"Bastos-Oreiro","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0046","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0047","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing based post-transplant monitoring of acute myeloid leukemia","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.009_bib0048","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bmt.2016.318","article-title":"Impact of Wilms\u2019 tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML","volume":"52","author":"Dul\u00e9ry","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0049","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/bloodadvances.2018025502","article-title":"Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells","volume":"3","author":"Kinsella","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.04.009_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.776946","article-title":"Long-term mixed chimerism after ex vivo\/in vivo T cell-depleted allogeneic hematopoietic cell transplantation in patients with myeloid neoplasms","volume":"11","author":"Ruhnke","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.04.009_bib0051","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbmt.2017.07.007","volume":"23","author":"Caldemeyer","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.009_bib0052","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/blood-2011-04-348805","article-title":"Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation","volume":"118","author":"Rettinger","year":"2011","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722012258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722012258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T19:47:48Z","timestamp":1726429668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722012258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2666636722012258"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}